Dietary polyphenol intake and risk of type 2 diabetes in the Polish arm of the Health, Alcohol and Psychosocial factors in Eastern Europe (HAPIEE) study

Giuseppe Grosso1,2,*, Urszula Stepaniak2, Agnieszka Micek2, Magdalena Kozela2, Denes Stefer3, Martin Bobak1 and Andrzej Pajak2
1Integrated Cancer Registry of Catania-Messina-Siracusa-Enna, Via S. Sofia 85, 95123, Catania, Italy
2Department of Epidemiology and Population Studies, Jagiellonian University Medical College, 20 Grzegorzecka Street, Krakow 31–531, Poland
3Department of Epidemiology and Public Health, University College London, 1–19 Torrington Place, London WC1E 6BT, UK

(Submitted 13 October 2016 – Final revision received 30 March 2017 – Accepted 3 May 2017)

Abstract
This study aimed to test the association between dietary content of total and individual classes of polyphenols and incident cases of type 2 diabetes in Polish adults participating to the Health, Alcohol and Psychosocial factors in Eastern Europe study. At baseline, diet by 148-item FFQ and health information were collected from 5806 participants free of diabetes. Self-reported incident type 2 diabetes was ascertained at 4-year follow-up visit. OR and 95% CI of type 2 diabetes comparing the various categories of polyphenol intake to the lowest one (reference category) and as a 1 SD increase modelled as continuous variable were calculated by performing age-, energy-, and multivariate-adjusted logistic regression models. During the follow-up, 456 incident cases of type 2 diabetes occurred. When comparing extreme quartiles, intake of total polyphenol was inversely associated with the risk of type 2 diabetes (OR 0.43; 95% CI 0.30, 0.61); 1 SD increase was associated with a reduced risk of diabetes (OR 0.68; 95% CI 0.59, 0.79). Among the main classes of polyphenols, flavonoids, phenolic acids, and stilbenes were independent contributors to this association. Both subclasses of phenolic acids were associated with decreased risk of type 2 diabetes, whereas among subclasses of flavonoids, high intake of flavonols, flavanones, flavones and anthocyanins was significantly associated with decreased risk of type 2 diabetes. Total dietary polyphenols and some classes of dietary polyphenols were associated with lower risk of type 2 diabetes.

Key words: Diabetes: Polyphenols: Flavonoids: Phenolic acids: Lignans: Stilbenes: Prospective studies

Plant-derived dietary pattern have been suggested to exert protection against metabolic disorders, such as type 2 diabetes(1). Among the most attractive hypotheses potentially explaining the benefits associated with high consumption of fruits and vegetables, polyphenols content is one of the best candidates as determinant of health. In fact, besides the known macro- and micronutrients contained in fruit and vegetables, polyphenols are highly representative in beverages such as coffee, tea and some alcoholic beverages that have demonstrated to have a positive impact on human health(2). Polyphenolic compounds are molecules highly contained in the aforementioned food and plant-derived beverages divided into four main classes on the basis of their chemical structure, including flavonoids, phenolic acids, stilbenes, and lignans, and ‘other’ polyphenols including various type of compounds(3). Overall, polyphenols comprise thousands of different molecules have been classified and described. Even though, the main challenges of studying these compounds rely on the identification of their potential effects in humans. In vitro studies demonstrate consistently antioxidant and anti-inflammatory effects at cellular and tissue level, but questions remain regarding their effective relevance for human health, as exposure in normal diet occur at lower concentrations than in laboratory setting(4,5).

Although causality is best supported by randomised trials, observational epidemiological studies also contribute to causal inference and are of great interest to evaluate the ‘real world’ consumption of polyphenols and their potential association with health outcomes. Regarding metabolic disorders, type 2 diabetes has been one of the most studied outcome evaluated in epidemiological studies. A relatively recent meta-analysis showed that increased intake of flavonoids, especially flavonols, may decrease the risk of type 2 diabetes(5). However, available data on type 2 diabetes prevalence and incidence is focused only on flavonoids. Only recently research has expanded to other polyphenol groups, such as phenolic acids and individual subgroups but data are overall scarce. Moreover, as polyphenol consumption varies with a great extent with the dietary habits of a population, it is of interest to collect

Abbreviation: HAPIEE, Health, Alcohol and Psychosocial factors in Eastern Europe.

* Corresponding author: G. Grosso, fax +39 0953782177, email giuseppe.grosso@studium.unict.it
Methods

Study population

The HAPIEE study is a multicenter prospective cohort study investigating the role of biological, dietary, lifestyle and environmental factors in cardiovascular and other chronic diseases\(^{(6)}\). Information on methods used are reported in detail elsewhere\(^{(5)}\). The present study was conducted on a subcohort of the Polish arm of the HAPIEE cohort (a random sample of 10,728 adults aged 45–69 years recruited in 2002–2005 (response ratio of 59%) in the urban area of Krakow, Poland) which was free of diabetes or impaired fasting glucose (fasting plasma glucose from 6.1 to 6.9 mmol/l) at baseline (n = 9420). Study participants completed a structured questionnaire and underwent to a clinical examination during the baseline data collection (wave I) and at follow-up visit (wave II). Participants were followed for a median follow-up period of 4 years (range 3.2–5.4 years). For the purpose of this study, only individuals free of diabetes at baseline who attended the last follow-up visit in 2006–2008 were included in the analysis (n = 5806, 54% of original cohort). Sample included in the analysis did not substantially differ in background characteristics or variables of interest concerning dietary habits. All participants provided written informed consent before joining the study.

Dietary assessment

Dietary data were collected by using a FFQ previously validated\(^{(7,8)}\). The FFQ consisted of 148 food and drink items accompanied by a country-specific instruction manual that included photographs to facilitate the estimation of portion sizes. Participants were asked how often, on average, they had consumed that amount of the item during the last 3 months, with nine responses ranging from ‘never or less than once per month’ to ‘six or more times per day’. Participants were also asked to include additional foods and frequency of consumption by manual entry.

Estimation of polyphenol intake

Data on the polyphenol content in foods were obtained from the Phenol-Explorer database (www.phenol-explorer.eu)\(^{(9)}\). The process of estimation of polyphenol intake has been described in details elsewhere\(^{(10)}\). In brief, food items of the FFQ containing more food components were separated according to their ingredients and foods that contained no polyphenols were excluded from the analysis. The average food consumption was calculated (in g or ml) by following the standard portion sizes used in the study and then converted in 24-h intake. An advanced search was carried out in the Phenol-Explorer database to retrieve mean content values for all polyphenols contained in the foods obtained and individual polyphenol intake from each food was calculated by multiplying the content of each polyphenol by the daily consumption of each food. Total polyphenol intake was calculated as the sum of all individual polyphenol intake from all food sources encountered according to this process. In this study we investigated exposure to total polyphenols and their main classes phenolic acids, flavonoids, stilbenes and lignans; the main subclasses of phenolic acids, including hydroxybenzoic acids and hydroxycinnamic acids; the main subclasses of flavonoids, including flavanols, flavonols, flavanones, flavones, anthocyanins, and isoflavones; and ‘other’ polyphenols, including alkylmethoxyphenols, alkylphenols, curcuminoinds, furanocoumarins, hydroxybenzaldehydes, hydroxybenzoketones, hydroxycinnamaldehydes, hydroxybenzoylketones, hydroxycinnamaldehydes, hydroxycoumarins, hydroxypseudopropenes, methoxyphenols, naphthoquinones, phenolic terpenes and tyrosols.

Demographic, lifestyle and clinical measurements

Socio-demographic and lifestyle characteristics included age, sex, educational and occupational level, smoking and alcohol drinking habits. Physical activity included energy expenditure in leisure time by reporting type and duration of activity according the predetermined questionnaire items. The overall amount of energy expenditure was estimated in kJ (kcal/d) and categorised in low, moderately and high activity level. Individuals were categorised according their smoking status as non-smoker and current smoker. Alcohol consumption was categorised as (i) non-drinkers (ii) drinkers; alcohol intake was considered as a continuous variable (g/d).

Physical examination included measurement of height, weight, waist circumference and blood pressure using standard procedures\(^{(6)}\). BMI was calculated according to the formula weight (kg)/height (m\(^2\)).

Outcome assessment

Participants were considered to have type 2 diabetes at baseline if they had elevated glucose concentrations (plasma glucose concentrations of ≥7 mmol/l) or treatment with hypoglycaemia medications (insulin or oral hypoglycaemia agent) within the last 2 weeks. Among individuals free of diabetes at baseline, cases of new type 2 diabetes were defined as those participants self-reporting of being professionally diagnosed with type 2 or taking hypoglycaemia medications within the last two weeks at follow-up.

Statistical analysis

We categorised individual flavonoids by dividing intake into quartiles and providing mean intakes for each category of exposure (expressed as glycosides and esters). Characteristics of the study cohort were described by quartiles of total polyphenol consumption. Sex-specific analyses were conducted. Descriptive presentation relied on cross tabulations. Continuous variables are presented as means and standard deviations, categorical variables as counts and percentages. Variables were examined for normality.
multivariable model were age, total energy intake, BMI, physical activity, educational status, smoking status, alcohol consumption, alcohol intake, fibre and menopausal status (women only). As Spearman correlation test showed significant correlation between main classes of polyphenols and subclasses of flavonoids (data not shown), we did not include in the model all main classes of polyphenols/flavanoids. Graphical representation using restricted cubic splines analysis for total polyphenols was applied. When examining the association with total polyphenols, a sensitivity analysis was performed by including one at the time the major food component. Statistical significance was accepted at \( P < 0.05 \). All statistical analyses were performed with SPSS for Windows 21.0 (SPSS Inc.).

**Results**

Baseline characteristics of individuals free of diabetes by quartiles of total polyphenol intake are presented in Table 1. Age and BMI were significantly lower with increasing polyphenol intake. In contrast, energy intake, fibre, alcohol drinkers and alcohol intake increased through quartiles of polyphenol consumption. Finally, among individuals with higher intake of polyphenols there were more smokers and physically active (Table 1). Major food contributors for total polyphenol intake were coffee and tea, representing the major contributors of phenolic acid and flavonoid classes, respectively (online Supplementary Table S1). Among fruits and vegetables, other important contributors of flavonoids were black currant, apples, strawberries, beans and oranges. Regarding lignans and stilbenes, major food sources were seeds and red wine, respectively; other polyphenols were mainly contained in beer, cereals, and coffee (online Supplementary Table S1).

During follow-up, 456 incident cases of type 2 diabetes occurred. In fully adjusted analyses, the highest intake of total

### Table 1. Background characteristics of participants in the Health, Alcohol and Psychosocial factors in Eastern Europe cohort free of diabetes at baseline by quartiles (Q) of total polyphenol intake (energy adjusted)

(Numbers and percentages; mean values and standard deviations)

| Polyphenol quartiles (men) | Q1 | Q2 | Q3 | Q4 | \( P_{\text{for trend}} \) |
|---------------------------|----|----|----|----|------------------|
| No. of subjects           | 1347 | 1454 | 1481 | 1524 | \( < 0.001 \) |
| Age (years)               |      |      |      |      |                  |
| Mean                      | 57.7 | 57.9 | 57.3 | 56.6 | <0.001           |
| SD                        | 6.9  | 6.9  | 6.8  | 6.8  |                  |
| Men                       | 645  | 656  | 698  | 732  | 0.632            |
| BMI (kg/m²)               |      |      |      |      |                  |
| Mean                      | 28.1 | 27.8 | 27.8 | 27.3 | <0.001           |
| SD                        | 4.3  | 4.3  | 4.3  | 4.1  |                  |
| Current smoker            | 409  | 451  | 454  | 528  | 0.022            |
| Educational level         |      |      |      |      |                  |
| Low                       | 135  | 162  | 143  | 134  | 0.056            |
| Medium                    | 818  | 859  | 895  | 878  | 0.010            |
| High                      | 389  | 430  | 443  | 512  | 0.06            |
| Physical activity level   |      |      |      |      |                  |
| Low                       | 385  | 401  | 377  | 398  | 0.001            |
| Medium                    | 483  | 517  | 534  | 530  | 0.001            |
| High                      | 409  | 452  | 498  | 522  | 0.001            |
| Alcohol drinkers          | 582  | 743  | 820  | 858  | 0.001            |
| Alcohol intake (g/d)      |      |      |      |      |                  |
| Mean                      | 2.16 | 2.34 | 2.99 | 3.31 | <0.001           |
| SD                        | 0.64 | 0.73 | 0.71 | 0.23 |                  |
| Total energy intake (kJ/d)|      |      |      |      |                  |
| Mean                      | 7524 | 8490 | 9345 | 10335 | 0.001            |
| SD                        | 2204 | 2178 | 2449 | 2833 | <0.001           |
| Total energy intake (kcal/d)|      |      |      |      |                  |
| Mean                      | 1798 | 2029 | 2233 | 2470 | 0.001            |
| SD                        | 526  | 520  | 585  | 677  | <0.001           |
| Fibre intake (mg/d)       |      |      |      |      |                  |
| Mean                      | 15.85| 18.02| 19.70| 22.17| <0.001           |
| SD                        | 5.53 | 5.94 | 7.18 | 8.94 |                  |
Table 2. Association between cumulative polyphenol intake (total and main groups) and incidence of type 2 diabetes (Mean values and standard deviations; odds ratios and 95 % confidence intervals)

| Polyphenol quartiles | Q1 OR (95 % CI) | Q2 OR (95 % CI) | Q3 OR (95 % CI) | Q4 OR (95 % CI) | P for trend | 1 SD increase OR (95 % CI) |
|----------------------|----------------|----------------|----------------|----------------|-------------|--------------------------|
| **Total polyphenols (mg/d)** | | | | | | |
| Mean | 1026·7 | 1469·6 | 1872·6 | 2632·1 | | |
| sd | 212·0 | 102·2 | 136·7 | 608·0 | | |
| No. of cases | 167 | 121 | 91 | 77 | | |
| Model 1 * | 1 | 0·69 | 0·54, 0·89 | 0·54 | 0·41, 0·71 | 0·47 | 0·35, 0·64 | <0·001 | 0·72 | 0·63, 0·81 |
| Model 2 † | 1 | 0·77 | 0·58, 1·01 | 0·48 | 0·35, 0·66 | 0·43 | 0·30, 0·61 | <0·001 | 0·68 | 0·59, 0·79 |
| **Total flavonoids (mg/d)** | | | | | | |
| Mean | 501·8 | 756·4 | 958·2 | 1452·3 | | |
| sd | 125·1 | 55·6 | 69·8 | 509·4 | | |
| No. of cases | 165 | 122 | 92 | 77 | | |
| Model 1 * | 1 | 0·76 | 0·59, 0·98 | 0·57 | 0·43, 0·75 | 0·53 | 0·39, 0·72 | <0·001 | 0·77 | 0·67, 0·89 |
| Model 2 † | 1 | 0·75 | 0·56, 0·99 | 0·50 | 0·36, 0·68 | 0·44 | 0·30, 0·63 | <0·001 | 0·72 | 0·61, 0·84 |
| **Phenolic acids (mg/d)** | | | | | | |
| Mean | 288·5 | 615·8 | 829·3 | 1482·0 | | |
| sd | 85·5 | 60·6 | 162·9 | 298·5 | | |
| No. of cases | 126 | 137 | 114 | 79 | | |
| Model 1 * | 1 | 1·03 | 0·80, 1·33 | 0·95 | 0·73, 1·25 | 0·64 | 0·47, 0·86 | <0·001 | 0·80 | 0·72, 0·90 |
| Model 2 † | 1 | 1·13 | 0·85, 1·50 | 0·92 | 0·68, 1·25 | 0·60 | 0·42, 0·84 | 0·001 | 0·80 | 0·71, 0·91 |
| **Stilbenes (mg/d)** | | | | | | |
| Mean | 0·004 | 0·016 | 0·046 | 0·598 | | |
| sd | 0·003 | 0·005 | 0·013 | 1·336 | | |
| No. of cases | 169 | 102 | 107 | 78 | | |
| Model 1 * | 1 | 0·60 | 0·46, 0·78 | 0·62 | 0·48, 0·81 | 0·40 | 0·30, 0·54 | <0·001 | 0·90 | 0·75, 1·07 |
| Model 2 † | 1 | 0·59 | 0·44, 0·79 | 0·54 | 0·40, 0·73 | 0·34 | 0·24, 0·48 | <0·001 | 0·92 | 0·77, 1·11 |
| **Lignans (mg/d)** | | | | | | |
| Mean | 0·16 | 0·24 | 0·31 | 1·36 | | |
| sd | 0·04 | 0·01 | 0·02 | 1·95 | | |
| No. of cases | 121 | 103 | 114 | 118 | | |
| Model 1 * | 1 | 0·98 | 0·74, 1·30 | 1·11 | 0·84, 1·45 | 1·25 | 0·95, 1·65 | 0·672 | 0·98 | 0·87, 1·11 |
| Model 2 † | 1 | 0·98 | 0·71, 1·34 | 1·15 | 0·85, 1·56 | 1·18 | 0·86, 1·61 | 0·534 | 1·00 | 0·88, 1·13 |

Q. quartile.
* Adjusted for age (continuous) and total energy intake (continuous).
† Model 1 = adjusted for BMI (continuous), physical activity (low/medium/high), educational status (low/medium/high), smoking status (yes/no), alcohol consumption (yes/no), alcohol intake (continuous), menopausal status (women only, yes/no) and dietary fibre (continuous).

Discussion

In this study we observed that individuals with higher total dietary polyphenol intake were less likely to develop type 2 diabetes compared with those in the lowest quartile of intake. Among individual classes studied, hydroxyphenolic acids and hydroxybenzoic acids among phenolic acids, and flavanols, flavanones, flavones and anthocyanins among flavonoids resulted to be associated with lower risk of type 2 diabetes.

Flavonoids are mainly contained in fruit, vegetable and tea, which have been associated with benefits toward metabolic disorders(31,12). These results are consistent with previous findings of the cross-sectional analysis of baseline data from the same cohort in which we found that the same classes of flavonoids were associated with lower odds of having impaired polyphenols was associated with lower risk of type 2 diabetes in the whole population (Table 2) and individually in both men and women (OR 0·31; 95 % CI 0·18, 0·52 and OR 0·53; 95 % CI 0·35, 0·85, respectively; online Supplementary Table S2) compared with the lowest. The relation was linear (Fig. 1) and 1 SD increased intake of polyphenols was associated with a 32 % reduced risk of diabetes (OR 0·68; 95 % CI 0·59, 0·79). The sensitivity analysis by adjusting for major food sources of polyphenols showed no differences with previous results (data not shown). Among the main classes of polyphenols, flavonoids, phenolic acids and stilbenes were contributors to this association. When considering individual subclass contributors among phenolic acids, both hydroxybenzoic acids and hydroxycinnamic acids showed an inverse relation with type 2 diabetes in a linear dose–response manner (Table 3). However, separate analyses by sex showed that higher intake of hydroxybenzoic acids was associated with decreased risk of type 2 diabetes mainly in men (online Supplementary Table S3). Among individual subclasses of flavonoids, flavanols, flavanones, flavones and anthocyanins were independently associated with decreased risk of type 2 diabetes in a linear dose–response manner (Table 4). Analyses separated by sexes showed similar results on flavones, whereas most of other results were more evident in men (online Supplementary Table S4). The association between other polyphenols and risk of type 2 diabetes resulted in null results for the whole cohort (Table 5) and individually for men and women (online Supplementary Table S5).
glucose metabolism\(^{13}\)). Such findings may explain the results of previous observations showing better outcomes related with plant-based dietary patterns in the HAPIEE cohort\(^{14-16}\). Recent prospective studies reported certain benefits for higher intakes of anthocyanins\(^{17}\), flavonols and flavonols\(^{18,19}\) despite contrasting results have been also published\(^{20,21}\). Findings from meta-analyses regarding the potential benefits of flavonoids on type 2 diabetes\(^{22}\) and glycaemic control\(^{23}\) also provided evidence of association between some flavonoid classes and decreased risk of type 2 diabetes. From a mechanistic point of view, flavonoids may reduce biological pathways related to the development of type 2 diabetes by improving endothelial function, which has been correlated with insulin resistance\(^{23}\).

Moreover, experimental studies in vitro and in vivo demonstrated that flavonoids interact with molecular targets and affect signalling pathways resulting in improvement of glycaemia and suppression of gluconeogenesis\(^{24-26}\). Despite we found some null results regarding the flavonol class, which has been previously related with health benefits associated with tea consumption\(^{27}\), some limitations of our study, including reverse causation and genetics related to high tea consumption may explain our unexpected findings.

In this study, hydroxybenzoic and hydroxycinnamic acids, the main subclasses of phenolic acids, were both inversely associated with the risk of type 2 diabetes. Among the most studied hydroxycinnamic acids, chlorogenic acids (CGA) which are contained in coffee, have been reported to exert beneficial effects towards cardiovascular risk factors and metabolic disorders\(^{28}\). We previously showed in the HAPIEE cohort the association between coffee and metabolic disorders, including type 2 diabetes\(^{29}\). Meta-analyses of observational studies conducted on coffee reported significant decreased risk of type 2 diabetes and general metabolic disorders\(^{12,30}\). Together with their antioxidant properties, CGA have been found to exert direct effects in regulating glucose metabolism\(^{31}\). CGA have been hypothesised to exert effects on glucose metabolism through their specific competitive inhibition of the glucose-6-phosphate translocase, which in turn inhibit gluconeogenesis, and activation of AMP-activated protein kinase, a sensor and regulator of cellular energy balance that may lead to suppression of hepatic glucose production and fatty acid synthesis\(^{32}\).

Studies on stilbenes have been mostly focused on the effects of resveratrol on cardio-metabolic health\(^{33}\). A recent meta-analysis on resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus reported a significant reduction of fasting glucose, insulin, glycated Hb (HbA1c) and insulin resistance levels in participants with type 2 diabetes\(^{34}\) but did not affect glycaemic measures in non-diabetic individuals\(^{35}\). We reported that high total stilbenes intake was related with decreased incidence of type 2 diabetes, thus confirming earlier findings derived from clinical setting. The main effects of stilbenes in human health are relative to their role in cellular defense against oxidative stress through the nuclear factor-erythroid-2-related

![Fig. 1. Association between total polyphenol intake and incidence of type 2 diabetes.](image-url)

### Table 3. Association between phenolic acid subclasses and incidence of type 2 diabetes

|                | Polyphenol quartiles |          |          |          |          |          |          |
|----------------|----------------------|----------|----------|----------|----------|----------|----------|
|                | Q1       | Q2       | Q3       | Q4       | P for trend | OR      | 95 % CI  |
| **Hydroxybenzoic acids (mg/d)** |          |          |          |          |          |          |          |
| Mean           | 43.4     | 85.7     | 91.9     | 157.1    |          | 43.4     | 95.1     |
| sd             | 23.5     | 9.9      | 3.7      | 31.4     |          | 23.5     | 31.4     |
| No. of cases   | 124      | 118      | 128      | 76       |          | 124      | 76       |
| Model 1\*      | 1        | 0.93     | 0.71     | 1.21     | 0.75     | 0.56     | 1.00     | 0.115    | 0.92    | 0.83, 1.02 |
| Model 2\†      | 1        | 1.05     | 0.78     | 1.42     | 1.18     | 0.87     | 1.60     | 0.71     | 0.51, 0.99 | 0.043    | 0.89    | 0.79, 0.99 |
| **Hydroxycinnamic acids (mg/d)** |          |          |          |          |          |          |          |
| Mean           | 188.19   | 530.67   | 724.48   | 1386.85  |          | 188.19   | 665.65   |
| sd             | 73.6     | 66.5     | 168.8    | 292.2    |          | 73.6     | 128.8    |
| No. of cases   | 127      | 128      | 121      | 80       |          | 127      | 121      |
| Model 1\*      | 1        | 0.95     | 0.73     | 1.23     | 1.01     | 0.77     | 1.32     | 0.64     | 0.47, 0.85 | <0.001   | 0.81    | 0.73, 0.91 |
| Model 2\†      | 1        | 1.08     | 0.81     | 1.44     | 0.99     | 0.73     | 1.34     | 0.61     | 0.43, 0.86 | 0.001    | 0.80    | 0.71, 0.91 |

Q, quartile.  
\* Adjusted for age (continuous) and total energy intake (continuous).  
\† Model 1 adjusted for BMI (continuous), physical activity (low/medium/high), educational status (low/medium/high), smoking status (yes/no), alcohol consumption (yes/no), alcohol intake (continuous), menopausal status (women only, yes/no) and dietary fibre (continuous).
Dietary polyphenols and diabetes risk

factor-2 (Nrf2) and the potential roles of SQSTM1/p62 protein in Nrf2/Keap1 signalling and autophagy.\(^{36}\) Moreover, modulation of expression of visfatin, sirtuin-1 and GLUT (2 and 4) may improve glucose metabolism by suppressing oxidative stress and increasing potential to internalise glucose by extrahepatic tissues.\(^{37}\) Besides the antioxidant effects, stilbenes have also been suggested to regulate circulating leptin levels and improve insulin signalling, both implicated in type 2 diabetes risk.\(^{38}\) However, the mechanisms of action for the hypothesised effects are by far complex and the knowledge on them is still evolving.

In the present study, no significant results were found for phyto-oestrogens, such as isoflavones and lignans. In our previous cross-sectional analysis, we found some positive association between impaired glucose metabolism and intake of isoflavones, which have a weak oestrogenic action. These findings are substantially in contrast with other recent studies showing that urinary excretion of isoflavones and lignans or markers of consumption were associated with lower risk of type 2 diabetes.\(^{39,40}\) However, other epidemiological studies reported contrasting results\(^{41}\) and analyses of large European and US cohorts showed no association of soy food intake, isoflavones and lignans and risk of type 2 diabetes.\(^{42,43}\) Consumption of soya foods in our cohort was very low and main food sources of phyto-oestrogens in non-Asian population are generally legumes, whole wheat

---

### Table 4. Association between flavonoid subclasses and incidence of type 2 diabetes (Mean values and standard deviations; odds ratios and 95% confidence intervals)

| Polyphenol quartiles | Q1 | Q2 | Q3 | Q4 | 1 so increase |
|----------------------|----|----|----|----|---------------|
| **Flavanols (mg/d)** |    |    |    |    |               |
| Mean                 | 323.65 | 519.72 | 681.84 | 1099.91 |               |
| No. of cases         | 151 | 139 | 86 | 80 |               |
| Model 1*             | 1 | 0.96 | 0.75, 1.23 | 0.60 | 0.65, 0.80 | 0.59 | 0.43, 0.79 | <0.001 | 0.77 | 0.67, 0.88 |
| Model 2†             | 1 | 0.88 | 0.67, 1.17 | 0.59 | 0.43, 0.81 | 0.54 | 0.39, 0.76 | 0.001 | 0.77 | 0.66, 0.90 |
| **Flavanones (mg/d)** |    |    |    |    |               |
| Mean                 | 60.16 | 89.63 | 113.64 | 163.31 |               |
| No. of cases         | 147.7 | 6.35 | 7.71 | 46.28 |               |
| Model 1*             | 1 | 1.00 | 0.77, 1.31 | 1.01 | 0.77, 1.33 | 1.12 | 0.84, 1.49 | 0.275 | 1.05 | 0.95, 1.16 |
| Model 2†             | 1 | 0.88 | 0.73, 1.35 | 0.98 | 0.72, 1.34 | 0.89 | 0.63, 1.26 | 0.368 | 0.94 | 0.82, 1.07 |
| **Flavones (mg/d)**  |    |    |    |    |               |
| Mean                 | 24.68 | 59.64 | 105.55 | 218.88 |               |
| No. of cases         | 114.4 | 11.05 | 15.86 | 89.61 |               |
| Model 1*             | 1 | 0.92 | 0.71, 1.19 | 0.79 | 0.60, 1.05 | 0.85 | 0.64, 1.13 | 0.178 | 0.92 | 0.82, 1.03 |
| Model 2†             | 1 | 0.88 | 0.66, 1.18 | 0.73 | 0.53, 1.00 | 0.75 | 0.54, 1.03 | 0.047 | 0.88 | 0.77, 0.99 |
| **Anthocyanins (mg/d)** |    |    |    |    |               |
| Mean                 | 4.40 | 8.75 | 14.52 | 91.92 |               |
| No. of cases         | 2.02 | 1.24 | 2.46 | 185.59 |               |
| Model 1*             | 1 | 1.32 | 1.01, 1.71 | 1.08 | 0.82, 1.42 | 0.87 | 0.65, 1.18 | 0.257 | 0.89 | 0.74, 1.08 |
| Model 2†             | 1 | 1.18 | 0.88, 1.59 | 0.86 | 0.62, 1.19 | 0.68 | 0.48, 0.98 | 0.070 | 0.82 | 0.66, 1.01 |
| **Isoflavones (mg/d)** |    |    |    |    |               |
| Mean                 | 0.001 | 0.140 | 0.196 | 4.912 |               |
| No. of cases         | 0.001 | 0.001 | 0.001 | 13.659 |               |
| Model 1*             | 1 | 0.91 | 0.68, 1.22 | 1.04 | 0.77, 1.41 | 0.90 | 0.65, 1.23 | 0.211 | 0.85 | 0.67, 1.09 |
| Model 2†             | 1 | 0.91 | 0.65, 1.28 | 1.00 | 0.71, 1.40 | 0.93 | 0.65, 1.34 | 0.065 | 0.75 | 0.55, 1.01 |
| **Dihydrochalcones (mg/d)** |    |    |    |    |               |
| Mean                 | 1.94 | 6.93 | 9.77 | 25.02 |               |
| No. of cases         | 1.22 | 1.69 | 1.09 | 7.74 |               |
| Model 1*             | 1 | 1.33 | 1.00, 1.76 | 1.05 | 0.77, 1.43 | 1.61 | 1.21, 2.12 | 0.004 | 1.15 | 1.04, 1.26 |
| Model 2†             | 1 | 1.07 | 0.78, 1.46 | 0.84 | 0.59, 1.19 | 1.12 | 0.80, 1.57 | 0.926 | 0.99 | 0.88, 1.12 |

Q. quartile

* Adjusted for age (continuous) and total energy intake (continuous).

† Model 1* adjusted for BMI (continuous), physical activity (low/medium/high), educational status (low/medium/high), smoking status (yes/no), alcohol consumption (yes/no), alcohol intake (continuous), menopausal status (women only, yes/no) and dietary fibre (continuous).
products and seeds(44). Clinical trials on flaxseeds and lignans and glycaemic control showed similar contrasting results(45,46). A meta-analysis of twenty-four intervention studies on soy and isoflavone intake and glycaemic control showed no significant effect on fasting glucose and insulin of eight trials with isoflavone extract and six studies with isolated soya protein, but reduction in fasting glucose concentrations in nine studies that used whole soya foods or soya diets (suggesting that components other than phyto-oestrogens may be responsible for the potential benefits(47).

Among other issues related to the contrasting results on phyto-oestrogens has been pointed out the large inter-individual variation in plasma concentrations of isoflavones, which may limit the use of intake data for risk assessment(48). Phyto-oestrogens have been hypothesised to ameliorate glucose metabolism and prevent type 2 diabetes by decreasing the activity of key enzymes related to blood glucose and HbA1c levels (including hepatic glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, fatty acid synthase, β-oxidation and carnitine palmitoyltransferase) and activating the PPAR gene expression pathway(49). However, given the aforementioned issues, further studies are needed to provide stronger evidence of the biological rationale.

Other limitations should be taken into account when considering results from this study. First, the observational design of the study can only partially provide evidence of causation. Second, due to relatively low response rate in the follow-up of the study can only partially provide evidence of causation. Considering results from this study. First, the observational design considering results from this study. First, the observational design may have led to underestimation of their effects by not taking into account possible interactions. Further studies with experimental design are needed to establish the effects that can materially affect the results. Fifth, consumption of some polyphenol classes (i.e. stilbenes, lignans and isoflavones) in normal diets can be difficult to be accurately estimated. Sixth, consumption of some polyphenol classes (i.e. stilbenes, lignans and isoflavones) in ‘normal’ diets can be negligible, and consequently difficult to be accurately estimated. Despite we adjusted the analyses for a number of potential confounders, other untested variables (i.e. family history of diabetes) may contribute to residual confounding.

### Table 5. Association between other polyphenols and incidence of type 2 diabetes (Mean values and standard deviations; odds ratios and 95% confidence intervals)

| Polyphenol quartiles | Q1 | Q2 | Q3 | Q4 |
|----------------------|----|----|----|----|
| OR 95% CI            |    |    |    |    |
| Others (mg/d)        |    |    |    |    |
| Mean                 | 6.17 | 16.8 | 32.92 | 76.66 |
| so                   | 3.02 | 3.10 | 5.65  | 37.81 |
| No. of cases         | 107 | 103 | 127  | 119  |
| Model 1†             | 1  | 0.92 | 0.69, 1.22 | 1.17  |
| Model 2†             | 1  | 0.94 | 0.68, 1.29 | 1.11  |

Q, quartile.

† Adjusted for age (continuous) and total energy intake (continuous).
specifically attributed to each polyphenol class in order to identify specific polyphenol-rich foods that may contribute to the prevention of cardiovascular risk factors.

Acknowledgements

The study has been funded by the Wellcome Trust (grant nos 064947/Z/01/Z and 081087/Z/06/Z), US National Institute on Ageing (grant no. 1R01 AG23522-01) and the MacArthur Foundation Initiative on Social Upheaval and Health (grant no. 71208). The funders had no role in study design, analysis or interpretation of the findings.

G. G. conceived the study, performed the analyses and wrote the manuscript; U. S. and M. K. collected the data and provided critical revision; A. M. and D. S. provided statistical advice and critical revision; M. B. and A. P. conceived the study, provided funding and critical revision.

The authors declare that there are no conflicts of interest.

Supplementary material

For supplementary material/s referred to in this article, please visit, please visit https://doi.org/10.1017/S0007114517001805

References

1. Maghsoudi Z, Ghiasvand R & Salehi-Abargouei A (2016) Empirically derived dietary patterns and incident type 2 diabetes mellitus: a systematic review and meta-analysis on prospective observational studies. Public Health Nutr 19, 230–241.

2. Amiot MJ, Riva C & Vinet A (2016) Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes Rev 17, 573–586.

3. Del Rio D, Rodriguez-Mateos A, Spencer JP, et al. (2013) Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal 18, 1818–1892.

4. Stedile N, Camuto R, de Cöl CD, et al. (2016) Dietary total antioxidant capacity is associated with plasmatic antioxidant capacity, nutrient intake and lipid and DNA damage in healthy women. Int J Food Sci Nutr 67, 479–488.

5. Liu YJ, Zhan J, Liu XL, et al. (2014) Dietary flavonoids intake and risk of type 2 diabetes: a meta-analysis of prospective cohort studies. Clin Nutr 33, 59–63.

6. Peasey A, Bobak M, Kubinova R, et al. (2006) Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: rationale and design of the HAPIEE study. BMC Public Health 6, 255.

7. Brunner E, Stallone D, Juneca M, et al. (2001) Dietary assessment in Whitehall II: comparison of 7 d diet diary and food-frequency questionnaire and validity against biomarkers. Br J Nutr 86, 405–414.

8. Willett WC, Sampson L, Stampfer MJ, et al. (1985) Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 122, 51–65.

9. Phenol-Explorer (2010) Phenol-Explorer: an online comprehensive database on polyphenol contents in foods. http://www.phenol-explorer.eu (accessed August 2016).

10. Grosso G, Stepaniak U, Topor-Madry R, et al. (2014) Estimated dietary intake and major food sources of polyphenols in the Polish arm of the HAPIEE study. Nutrition 30, 1398–1403.

11. Shin JY, Kim JY, Kang HT, et al. (2015) Effect of fruits and vegetables on metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Int J Food Sci Nutr 66, 416–425.

12. Marventano S, Salomone F, Godos J, et al. (2016) Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr 35, 1269–1281.

13. Grosso G, Stepaniak U, Micek A, et al. (2016) Dietary polyphenols are inversely associated with metabolic syndrome in Polish adults of the HAPIEE study. Eur J Nutr 56, 1409–1420.

14. Grosso G, Stepaniak U, Micek A, et al. (2015) A Mediterranean-type diet is associated with better metabolic profile in urban Polish adults: results from the HAPIEE study. Metabolism 64, 738–746.

15. Stefer D, Pilhart H, Jankovic N, et al. (2014) Healthy diet indicator and mortality in Eastern European populations: prospective evidence from the HAPIEE cohort. Eur J Clin Nutr 68, 1346–1352.

16. Stepaniak U, Micek A, Grosso G, et al. (2016) Antioxidant vitamin intake and mortality in three Central and Eastern European urban populations: the HAPIEE study. Eur J Nutr 55, 547–560.

17. Wedick NM, Pan A, Cassidy A, et al. (2012) Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr 95, 925–933.

18. Jacques PF, Cassidy A, Rogers G, et al. (2013) Higher dietary flavonoid intake is associated with lower incidence of type 2 diabetes. J Nutr 143, 1474–1480.

19. Zamora-Ros R, Forouhi NG, Sharp SJ, et al. (2014) Dietary intakes of individual flavonoids and flavonols are inversely associated with incident type 2 diabetes in European populations. J Nutr 144, 335–343.

20. Nettleton JA, Harnack LJ, Scafford CG, et al. (2006) Dietary flavonoids and flavonoid-rich foods are not associated with risk of type 2 diabetes in postmenopausal women. J Nutr 136, 3039–3045.

21. Song Y, Manson JE, Buring JE, et al. (2005) Associations of dietary flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic inflammation in women: a prospective study and cross-sectional analysis. J Am Coll Nutr 24, 376–384.

22. Zheng XX, Xu YL, Li SH, et al. (2013) Effects of green tea catechins with or without caffeine on glycemic control in diabetic mice. Nutr Metab Cardiovasc Dis 23, 746–752.

23. Munir KM, Chandrasekaran S, Gao F, et al. (2013) Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: therapeutic implications for diabetes and its cardiovascular complications. Am J Physiol Endocrinol Metab 305, E679–E686.

24. Sasaki R, Nishimura H, Hoshino H, et al. (2007) Cyanidin-3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice. Biochem Pharmacol 74, 1619–1627.

25. Scacciozzi B, Vani R, Filiesi G, et al. (2011) Cyanidin-3-O-beta-glucoside and protocatechuic acid exert insulin-like effects by upregulating PPARGamma activity in human umbilical vein endothelial cells. Diabetes 60, 2234–2244.

26. Takikawa M, Inoue S, Horio F, et al. (2010) Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice. J Nutr 140, 527–533.

27. InterAct C, van den Berghen GJ, Kuistinen A, et al. (2012) Tea consumption and incidence of type 2 diabetes in Europe: the EPIC-InterAct case-cohort study. PLOS ONE 7, e36910.
28. Buscemi S, Marventano S, Antoci M, et al. (2016) Coffee and metabolic impairment: An updated review of epidemiological studies. *NFS Journal* **3**, 1–7.

29. Grosso G, Stepaniak U, Micek A, et al. (2015) Association of daily coffee and tea consumption and metabolic syndrome: results from the Polish arm of the HAPIEE study. *Eur J Nutr* **54**, 1129–1137.

30. Jiang X, Zhang D & Jiang W (2014) Coffee and caffeine intake and incidence of type 2 diabetes mellitus: a meta-analysis of prospective studies. *Eur J Nutr* **53**, 25–38.

31. Godos J, Pluchinotta FR, Marventano S, et al. (2014) Coffee components and cardiovascular risk: beneficial and detrimental effects. *Int J Food Sci Nutr* **65**, 925–936.

32. Meng S, Cao J, Feng Q, et al. (2013) Roles of chlorogenic acid on regulating glucose and lipids metabolism: a review. *Evid Based Complement Alternat Med* **2013**, 801457.

33. Riccioni G, Gammone MA, Tettamanti G, et al. (2015) Resveratrol and anti-atherogenic effects. *Int J Food Sci Nutr* **66**, 603–610.

34. Haugenlas HA, Schoula JA & Smoliga JM (2015) Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus – systematic review and meta-analysis. *Mol Nutr Food Res* **59**, 147–159.

35. Liu K, Zhou R, Wang B, et al. (2014) Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. *Am J Clin Nutr* **99**, 1510–1519.

36. Reinsalmo M, Karlund A, Koskela A, et al. (2015) Polyphenol stilbenes: molecular mechanisms of defence against oxidative stress and aging-related diseases. *Oxid Med Cell Longev* **2015**, 340520.

37. Gencoglu H, Tuzcu M, Hayirli A, et al. (2015) Protective effects of resveratrol against streptozotocin-induced diabetes in rats by modulation of visfatin/sirtuin-1 pathway and glucose transporters. *Int J Food Sci Nutr* **66**, 514–520.

38. Petrovski G, Gurusamy N & Das DK (2011) Resveratrol in cardiovascular health and disease. *Ann N Y Acad Sci* **1215**, 22–33.

39. Ding M, Franke AA, Rosner BA, et al. (2015) Urinary isoflavonoids and risk of type 2 diabetes: a prospective investigation in US women. *Br J Nutr* **114**, 1694–1701.

40. Sun Q, Wedick NM, Pan A, et al. (2014) Gut microbiota metabolites of dietary lignans and risk of type 2 diabetes: a prospective investigation in two cohorts of U.S. women. *Diabetes Care* **37**, 1287–1295.

41. Ko KP, Kim CS, Ahn Y, et al. (2015) Plasma isoflavone concentration is associated with decreased risk of type 2 diabetes in Korean women but not men: results from the Korean Genome and Epidemiology Study. *Diabetologia* **58**, 726–735.

42. Ding M, Pan A, Manson JE, et al. (2016) Consumption of soy foods and isoflavones and risk of type 2 diabetes: a pooled analysis of three US cohorts. *Eur J Clin Nutr* **70**, 1381–1387.

43. Zamora-Ros R, Forouhi NG, Sharp SJ, et al. (2013) The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in European populations: the EPIC-InterAct study. *Diabetes Care* **36**, 3961–3970.

44. Chan CY, Kamil A & Blumberg JB (2015) Phytochemical composition and antioxidant capacity of whole wheat products. *Int J Food Sci Nutr* **66**, 63–70.

45. Billingsky J, Glew RA, Cornish SM, et al. (2013) No evidence of hypoglycemia or hypotension in older adults during 6 months of flax lignan supplementation in a randomized controlled trial: a safety evaluation. *Pharm Biol* **51**, 778–782.

46. Wu JH, Hodgson JM, Puddey IB, et al. (2009) Sesame supplementation does not improve cardiovascular disease risk markers in overweight men and women. *Nutr Metab Cardiovasc Dis* **19**, 774–780.

47. Liu ZM, Chen YM & Ho SC (2011) Effects of soy intake on glycemic control: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* **93**, 1092–1101.

48. van der Velpen V, Hollman PC, van Nielen M, et al. (2014) Large inter-individual variation in isoflavone plasma concentration limits use of isoflavone intake data for risk assessment. *Eur J Clin Nutr* **68**, 1141–1147.

49. Talaei M & Pan A (2015) Role of phytoestrogens in prevention and management of type 2 diabetes. *World J Diabetes* **6**, 271–283.

50. Galea S & Tracy M (2007) Participation rates in epidemiologic studies. *Ann Epidemiol* **17**, 643–655.

51. Nohr EA, Frydenberg M, Henriksen TB, et al. (2013) No evidence of hypoglycemia or hypotension in older adults during 6 months of flax lignan supplementation in a randomized controlled trial: a safety evaluation. *Pharm Biol* **51**, 778–782.